Safety and feasibility of mitraclip implantation in patients with acute mitral regurgitation after recent myocardial infarction and severe left ventricle dysfunction
Haberman, Dan (Heart Center. Kaplan Medical Center. Affiliated to the Hebrew University)
Estevez-Loureiro, Rodrigo (Hospital Álvaro Cunqueiro (Vigo))
Benito-González, Tomás (Complejo Asistencial Universitario de León)
Denti, Paolo (San Raffaele University Hospital)
Arzamendi, Dabit (Institut d'Investigació Biomèdica Sant Pau)
Adamo, Marianna (Cardiac Catheterization Laboratory. ASST Spedali Civili di Brescia)
Freixa, Xavier (Hospital Clínic i Provincial de Barcelona)
Nombela-Franco, Luís (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos)
Villablanca, Pedro (Interventional Cardiology. The Center for Structural Heart Disease. Henry Ford Hospital)
Krivoshei, Lian (Department of Cardiology. Kantonsspital Baden)
Fam, Neil (Division of Cardiology. St. Michael's Hospital. University of Toronto)
Spargias, Konstantinos (Department of Transcatheter Heart Valves. HYGEIA Hospital)
Czarnecki, Andrew (Schulich Heart Centre. Sunnybrook Health Sciences Centre. University of Toronto)
Pascual, Isaac (Universitario Central de Asturias)
Praz, Fabien (Inselspital. Bern University Hospital. University of Bern)
Sudarsky, Doron (Cardiovascular Institute. Baruch Padeh Medical Center)
Kerner, Arthur (Department of Cardiology. Rambam Medical Center. and B. Rappaport Faculty of Medicine. Technion Medical School)
Ninios, Vlasis (Department of Cardiology. Interbalkan European Medical Center)
Gennari, Marco (Heart Valve Clinic. University Hospital of Zurich)
Beeri, Ronen (Heart Institute. Hadassah-Hebrew University Medical Center)
Perl, Leor (Cardiology Department. Rabin Medical Center and the "Sackler" Faculty of Medicine. Tel-Aviv University)
Danenberg, Haim (Heart Institute. Hadassah-Hebrew University Medical Center)
Poles, Lion (Heart Center. Kaplan Medical Center. Affiliated to the Hebrew University)
Shimoni, Sara (Heart Center. Kaplan Medical Center. Affiliated to the Hebrew University)
Goland, Sorel (Heart Center. Kaplan Medical Center. Affiliated to the Hebrew University)
Caneiro-Queija, Berenice (Hospital Álvaro Cunqueiro (Vigo))
Scianna, Salvatore (Heart Valve Clinic. University Hospital of Zurich)
Moaraf, Igal (Department of Cardiology. Kantonsspital Baden)
Schiavi, Davide (Cardiovascular Surgery Department. San Raffaele University Hospital)
Scardino, Claudia (Hospital Universitari Joan XXIII de Tarragona)
Corpataux, Noé (Inselspital. Bern University Hospital. University of Bern)
Echarte-Morales, Julio (Complejo Asistencial Universitario de Leon)
Chrissoheris, Michael (HYGEIA Hospital)
Fernández-Peregrina, Estefanía (Institut d'Investigació Biomèdica Sant Pau)
Di Pasquale, Mattia (Cardiac Catheterization Laboratory. ASST Spedali Civili di Brescia)
Regueiro, Ander (Interventional Cardiology Unit. Hospital Clinic)
Vergara-Uzcategui, Carlos (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos)
Iñiguez-Romo, Andres (Hospital Álvaro Cunqueiro (Vigo))
Fernández-Vázquez, Felipe (Complejo Asistencial Universitario de Leon)
Dvir, Danny (Jesselson Integrated Heart Centre. Shaare Zedek Medical Center. Hebrew University)
Taramasso, Maurizio (Heart Valve Clinic. University Hospital of Zurich)
Shuvy, Mony (Jesselson Integrated Heart Centre. Shaare Zedek Medical Center. Hebrew University)

Data:	2021
Resum:	Patients with severe mitral regurgitation (MR) after myocardial infarction (MI) have an increased risk of mortality. Transcatheter mitral valve repair may therefore be a suitable therapy. However, data on clinical outcomes of patients in an acute setting are scarce, especially those with reduced left ventricle (LV) dysfunction. We conducted a multinational, collaborative data analysis from 21 centers for patients who were, within 90 days of acute MI, treated with MitraClip due to severe MR. The cohort was divided according to median left ventricle ejection fraction (LVEF)-35%. Included in the study were 105 patients. The mean age was 71 ± 10 years. Patients in the LVEF < 35% group were younger but with comparable Euroscore II, multivessel coronary artery disease, prior MI and coronary artery bypass graft surgery. Procedure time was comparable and acute success rate was high in both groups (94% vs. 90%, p = 0. 728). MR grade was significantly reduced in both groups along with an immediate reduction in left atrial V-wave, pulmonary artery pressure and improvement in New York Heart Association (NYHA) class. In-hospital and 1-year mortality rates were not significantly different between the two groups (11% vs. 7%, p = 0. 51 and 19% vs. 12%, p = 0. 49) and neither was the 3-month re-hospitalization rate. In conclusion, MitraClip intervention in patients with acute severe functional mitral regurgitation (FMR) due to a recent MI in an acute setting is safe and feasible. Even patients with severe LV dysfunction may benefit from transcatheter mitral valve intervention and should not be excluded.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Mitral regurgitation ; Percutaneous mitral valve repair ; Acute myocardial infarction ; Left ventricle dysfunction
Publicat a:	Journal of clinical medicine, Vol. 10 Núm. 9 (january 2021) , p. 1819, ISSN 2077-0383

DOI: 10.3390/jcm10091819
PMID: 33921996

14 p, 2.4 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats